Approval of Pembrolizumab Enfortumab Therapy: Insights on Efficacy, Costs, and Patient Eligibility

By João L. Carapinha

April 8, 2025

The German Federal Joint Committee (G-BA) has approved a new indication for Pembrolizumab Enfortumab therapy in combination with Enfortumab Vedotin as a first-line treatment for adult patients with unresectable or metastatic urothelial carcinoma. This decision is based on a structured benefit assessment comparing this therapy to standard treatments. It focuses on patients’ eligibility for cisplatin-based regimens. For those ineligible for either cisplatin or carboplatin, no additional benefit was found.

Clinical Effectiveness Overview

  • Mortality Benefits: In cisplatin-eligible patients, the combination therapy showed a mortality benefit but lacked quantifiable superiority over cisplatin/gemcitabine. For carboplatin-eligible patients, it demonstrated significant mortality improvement compared to carboplatin/gemcitabine, along with symptomatic benefits like reduced nausea and constipation. However, for patients ineligible for both, no efficacy was shown over alternatives like Atezolizumab monotherapy or best supportive care.

Economic Aspects

  • Cost Implications: The annual treatment costs for Pembrolizumab Enfortumab therapy are much higher than standard therapies, estimated at €181,464 per patient. Standard options include carboplatin, and gemcitabine, or maintenance therapy with avelumab, depending on the regimen and patient subgroup.

Safety Profile and Adverse Events

  • Benefits and Risks: The combination therapy has advantages, such as fewer severe adverse effects, and risks, including immune-related side effects like severe hyperglycemia.

Regulatory and Assessment Framework

The G-BA conducts early benefit assessments under the Arzneimittelmarkt-Neuordnungsgesetz (AMNOG). This process compares new therapies against existing standards to ensure efficient resource use in Germany’s statutory health insurance (GKV) system. Pembrolizumab is a PD-1 checkpoint inhibitor, while Enfortumab Vedotin is an antibody-drug conjugate targeting Nectin-4.

Implications for Healthcare Economics and Access

  1. Healthcare Economics: The high cost of Pembrolizumab Enfortumab therapy raises affordability concerns. Its benefits for some subpopulations may limit widespread use.
  2. Reimbursement Challenges: High costs and limited evidence for certain groups may hinder reimbursement. Price negotiations with GKV payers could lead to reductions.
  3. Addressing Unmet Needs: The lack of benefits for cisplatin- and carboplatin-ineligible patients highlights the need for alternative treatments. More research could improve outcomes.

Final Reflections

The G-BA’s decision reflects a tailored approach to clinical effectiveness. While Pembrolizumab Enfortumab therapy shows promise for select groups, its high costs and selective effectiveness emphasize the need for precision medicine and cost containment. For details, see the G-BA’s official assessment.

Reference url

Recent Posts

PhRMA’s Patient Access Investment: $500 Billion Commitment to Domestic Infrastructure and Care

By HEOR Staff Writer

September 30, 2025

Yesterday PhRMA announced steps to boosting patient access to treatments. The announcement showcases the U.S. biopharmaceutical industry’s initiative to enhance patient access and stimulate economic growth. The announcement outlines a remarkable $500 billion in new U.S. infrastructure spending. I...
Sanofi Insulin Savings: Your Comprehensive Guide for 2025

By HEOR Staff Writer

September 29, 2025

Are you searching for effective Sanofi insulin savings options to manage diabetes medication costs in 2025? The Sanofi Patient Connection Savings Registration program offers an efficient pathway for eligible patients to save on key insulin products—helping reduce out-of-pocket expenses and promot...
Empowering Innovation: Clinical Trials Reform Strategies by EMA for 2025
The recently published European Medicines Agency (EMA) article addresses the strategic targets for improving the clinical trials reform landscape in Europe. It emphasizes measures that foster innovation, collaboration, and efficiency in clinical research. The article outlines new priorities for 2...